Clinical Significance of Heparanase Splice Variant (T5) in Renal Cell Carcinoma: Evaluation by a Novel T5-Specific Monoclonal Antibody

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Barash, Uri ^a   Arvatz, Gil ^a   Farfara, Roy ^b   Naroditsky, Inna ^c   Doweck, Ilana ^d   Feld, Sari ^a   Ben Izhak, Ofer ^c   Ilan, Neta ^a   Nativ, Ofer ^b   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9C9; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER TISSUE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; TUMOR BIOPSY; WILD TYPE;

ALTERNATIVE SPLICING; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DEMOGRAPHY; FEMALE; GLUCURONIDASE; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MALE; STAINING AND LABELING;

EID: 84871202658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051494     Document Type: Article

References (41)

1. Dempsey LA, Brunn GJ, Platt JL, (2000) Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25: 349-351.
2. Parish CR, Freeman C, Hulett MD, (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471: M99-108.
3. Vlodavsky I, Friedmann Y, (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347.
4. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, et al. (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 285: 28010-28019.
5. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, et al. (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276: 1170-1177.
6. Ilan N, Elkin M, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38: 2018-2039.
7. Vreys V, David G, (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11: 427-452.
8. Casu B, Vlodavsky I, Sanderson RD, (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36: 195-203.
9. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I, (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30: 253-268.
10. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, et al. (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277: 3890-3903.
11. Fux L, Ilan N, Sanderson RD, Vlodavsky I, (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34: 511-519.
12. Levy-Adam F, Ilan N, Vlodavsky I, (2010) Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 20: 153-160.
13. Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD, (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286: 6490-6499.
14. Cooper TA, Wan L, Dreyfuss G, (2009) RNA and disease. Cell 136: 777-793.
15. Tazi J, Bakkour N, Stamm S, (2009) Alternative splicing and disease. Biochim Biophys Acta 1792: 14-26.
16. van Alphen RJ, Wiemer EA, Burger H, Eskens FA, (2009) The spliceosome as target for anticancer treatment. Br J Cancer 100: 228-232.
17. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, et al. (2010) A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 24: 1239-1248.
18. Gingis-Velitski S, Ishai-Michaeli R, Vlodavsky I, Ilan N, (2007) Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J 21: 3986-3993.
19. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, et al. (2006) An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341: 958-963.
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds.) (2010) AJCC Cancer Staging Manual. 7th Edition, New York, NY, Springer.
21. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, et al. (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123: 2566-2573.
22. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, et al. (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8: 1055-1061.
23. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N, (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68: 10077-10085.
24. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, et al. (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43: 1862-1873.
25. Dempsey LA, Plummer TB, Coombes SL, Platt JL, (2000) Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 10: 467-475.
26. Haimov-Kochman R, Friedmann Y, Prus D, Goldman-Wohl DS, Greenfield C, et al. (2002) Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod 8: 566-573.
27. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, et al. (2004) Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117: 2249-2258.
28. Skotheim RI, Nees M, (2007) Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39: 1432-1449.
29. Srebrow A, Kornblihtt AR, (2006) The connection between splicing and cancer. J Cell Sci 119: 2635-2641.
30. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
31. Weidle UH, Maisel D, Klostermann S, Weiss EH, Schmitt M, (2011) Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics Proteomics 8: 211-226.
32. White ES, Baralle FE, Muro AF, (2008) New insights into form and function of fibronectin splice variants. J Pathol 216: 1-14.
33. Bertolesi GE, Su HY, Michaiel G, Dueck SM, Hehr CL, et al. (2011) Two promoters with distinct activities in different tissues drive the expression of heparanase in Xenopus. Dev Dyn 240: 2657-2672.
34. Nasser NJ, Avivi A, Shushy M, Vlodavsky I, Nevo E, (2007) Cloning, expression, and characterization of an alternatively spliced variant of human heparanase. Biochem Biophys Res Commun 354: 33-38.
35. Nasser NJ, Nevo E, Shafat I, Ilan N, Vlodavsky I, et al. (2005) Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant. PNAS 102: 15161-15166.
36. Sato M, Amemiya K, Hayakawa S, Munakata H, (2008) Subcellular localization of human heparanase and its alternative splice variant in COS-7 cells. Cell Biochem Funct 26: 676-683.
37. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML, (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624.
38. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566.
39. Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, et al. (2008) Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res 14: 6055-6061.
40. Ren J, Liu H, Yan L, Tian S, Li D, et al. (2011) Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significances. World J Surg Oncol 9: 158.
41. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, et al. (2009) Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 69: 1758-1767.